[ 18F]THK-5351 PET Patterns in Patients With Alzheimer’s Disease and Negative Amyloid PET Findings
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Alzheimer’s disease (AD) does not always mean amyloid positivity. [18F]THK-5351 has been shown to be able to detect reactive astrogliosis as well as tau accompanied by neurodegenerative changes. We evaluated the [18F]THK-5351 retention patterns in positron-emission tomography (PET) and the clinical characteristics of patients clinically diagnosed with AD dementia who had negative amyloid PET findings. Methods We performed 3.0-T magnetic resonance imaging, [18F]THK-5351 PET, and amyloid PET in 164 patients with AD dementia. Amyloid PET was visually scored as positive or negative. [18F]THK-5351 PET were visually classified as having an intratemporal or extratemporal spread pattern. Results The 164 patients included 23 (14.0%) who were amyloid-negative (age 74.9±8.3 years, mean±standard deviation; 9 males, 14 females). Amyloid-negative patients were older, had a higher prevalence of diabetes mellitus, and had better visuospatial and memory functions. The frequency of the apolipoprotein E ε4 allele was higher and the hippocampal volume was smaller in amyloid-positive patients. [18F]THK-5351 uptake patterns of the amyloid-negative patients were classified into intratemporal spread (n=10) and extratemporal spread (n=13). Neuropsychological test results did not differ significantly between these two groups. The standardized uptake value ratio of [18F]THK-5351 was higher in the extratemporal spread group (2.01±0.26 vs. 1.61±0.15, p=0.001). After 1 year, Mini Mental State Examination (MMSE) scores decreased significantly in the extratemporal spread group (-3.5±3.2, p=0.006) but not in the intratemporal spread group (-0.5±2.8, p=0.916). The diagnosis remained as AD (n=5, 50%) or changed to other diagnoses (n=5, 50%) in the intratemporal group, whereas it remained as AD (n=8, 61.5%) or changed to frontotemporal dementia (n=4, 30.8%) and other diagnoses (n=1, 7.7%) in the extratemporal spread group. Conclusions Approximately 70% of the patients with amyloid-negative AD showed abnormal [18F]THK-5351 retention. MMSE scores deteriorated rapidly in the patients with an extratemporal spread pattern.
Abstract
Background and Purpose Alzheimer’s disease (AD) does not always mean amyloid positivity. [18F]THK-5351 has been shown to be able to detect reactive astrogliosis as well as tau accompanied by neurodegenerative changes. We evaluated the [18F]THK-5351 retention patterns in positron-emission tomography (PET) and the clinical characteristics of patients clinically diagnosed with AD dementia who had negative amyloid PET findings. Methods We performed 3.0-T magnetic resonance imaging, [18F]THK-5351 PET, and amyloid PET in 164 patients with AD dementia. Amyloid PET was visually scored as positive or negative. [18F]THK-5351 PET were visually classified as having an intratemporal or extratemporal spread pattern. Results The 164 patients included 23 (14.0%) who were amyloid-negative (age 74.9±8.3 years, mean±standard deviation; 9 males, 14 females). Amyloid-negative patients were older, had a higher prevalence of diabetes mellitus, and had better visuospatial and memory functions. The frequency of the apolipoprotein E ε4 allele was higher and the hippocampal volume was smaller in amyloid-positive patients. [18F]THK-5351 uptake patterns of the amyloid-negative patients were classified into intratemporal spread (n=10) and extratemporal spread (n=13). Neuropsychological test results did not differ significantly between these two groups. The standardized uptake value ratio of [18F]THK-5351 was higher in the extratemporal spread group (2.01±0.26 vs. 1.61±0.15, p=0.001). After 1 year, Mini Mental State Examination (MMSE) scores decreased significantly in the extratemporal spread group (-3.5±3.2, p=0.006) but not in the intratemporal spread group (-0.5±2.8, p=0.916). The diagnosis remained as AD (n=5, 50%) or changed to other diagnoses (n=5, 50%) in the intratemporal group, whereas it remained as AD (n=8, 61.5%) or changed to frontotemporal dementia (n=4, 30.8%) and other diagnoses (n=1, 7.7%) in the extratemporal spread group. Conclusions Approximately 70% of the patients with amyloid-negative AD showed abnormal [18F]THK-5351 retention. MMSE scores deteriorated rapidly in the patients with an extratemporal spread pattern.
참고문헌 (51)
- Alzheimer’s Association, "Alzheimer’s disease facts and figures", Alzheimers Dement, 16, pp.391~460 (2020)
- World Alzheimer report 2015 the global impact of dementia: an analysis of prevalence, incidence, cost & trends, "Prince MJ", Alzheimer’s Disease International, ~ (2015)
- McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
- Beach TG, "Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010", J Neuropathol Exp Neurol, 71, pp.266~273 (2012)
- Knopman DS, "Practice parameter : diagnosis of dementia(an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology", Neurology, 56, pp.1143~1153 (2001)
- Salloway S, "Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease", N Engl J Med, 370, pp.322~333 (2014)
- Doody RS, "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease", N Engl J Med, 370, pp.311~321 (2014)
- Klunk WE, "Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B", Ann Neurol, 55, pp.306~319 (2004)
- Barthel H, "Cerebral amyloid-β PET with florbetaben(18F)in patients with Alzheimer’s disease and healthy controls : a multicentre phase 2 diagnostic study", Lancet Neurol, 10, pp.424~435 (2011)
- Vandenberghe R, "18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment : a phase 2 trial", Ann Neurol, 68, pp.319~329 (2010)
- Clark CM, "Use of florbetapir-PET for imaging beta-amyloid pathology", JAMA, 305, pp.275~283 (2011)
- Ossenkoppele R, "Prevalence of amyloid PET positivity in dementia syndromes : a meta-analysis", JAMA, 313, pp.1939~1949 (2015)
- Barkhof F, "The significance of medial temporal lobe atrophy : a postmortem MRI study in the very old", Neurology, 69, pp.1521~1527 (2007)
- Serrano-Pozo A, "Mild to moderate Alzheimer dementia with insufficient neuropathological changes", Ann Neurol, 75, pp.597~601 (2014)
- Crary JF, "Primary age-related tauopathy(PART) : a common pathology associated with human aging", Acta Neuropathol, 128, pp.755~766 (2014)
- Harada R, "18F-THK5351 : a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease", J Nucl Med, 57, pp.208~214 (2016)
- Harada R, "Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease", J Nucl Med, 59, pp.671~674 (2018)
- Ng KP, "Monoamine oxidase B inhibitor, selegiline, reduces 18FTHK5351uptake in the human brain", Alzheimers Res Ther, 9, pp.25~ (2017)
- McKhann G, "Clinical diagnosis of Alzheimer’s disease : report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease", Neurology, 34, pp.939~944 (1984)
- Noh Y, "A new classification system for ischemia using a combination of deep and periventricular white matter hyperintensities", J Stroke Cerebrovasc Dis, 23, pp.636~642 (2014)
- Kang Y, "Seoul Neuropsychological Screening Battery" (2003), Human Brain Research & Consulting Co
- Rascovsky K, "Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia", Brain, 134, pp.2456~2477 (2011)
- Román GC, "Subcortical ischaemic vascular dementia", Lancet Neurol, 1, pp.426~436 (2002)
- McKeith IG, "Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies(DLB) : report of the consortium on DLB international workshop", Neurology, 47, pp.1113~1124 (1996)
- McKeith IG, "Diagnosis and management of dementia with Lewy bodies : third report of the DLB consortium", Neurology, 65, pp.1863~1872 (2005)
- Joshi A, "Reducing between scanner differences in multi-center PET studies", Neuroimage, 46, pp.154~159 (2009)
- Sonni I, "Evaluation of a visual interpretation method for tau-PET with 18F-flortaucipir", Alzheimers Dement(Amst), 12, pp.e12133~ (2020)
- Son HJ, "Differences in gray and white matter 18F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias", Eur J Nucl Med Mol Imaging, 46, pp.357~366 (2019)
- "NEURACEQ (florbetaben F 18 injection), for intravenous use: prescribing information" (2014)[URL]
- "Vizamyl (flutemetamol F 18 injection) for intravenous use: prescribing information" (2017)[URL]
- Thomas BA, "The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease", Eur J Nucl Med Mol Imaging, 38, pp.1104~1119 (2011)
- Sattarivand M, "Symmetric geometric transfer matrix partial volume correction for PET imaging : principle, validation and robustness", Phys Med Biol, 57, pp.7101~7116 (2012)
- Son HJ, "The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases", Eur J Nucl Med Mol Imaging, 47, pp.332~341 (2020)
- Thurfjell L, "Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid : concordance with visual image reads", J Nucl Med, 55, pp.1623~1628 (2014)
- Ward A, "Prevalence of apolipoprotein E4 genotype and homozygotes(APOE e4", 4)among patients diagnosed with Alzheimer’s disease : a systematic review and meta-analysis, 2012, pp.38, 1~17
- Altamura C, "What is the relationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia?", Eur J Neurol, 14, pp.679~682 (2007)
- Efthymiou AG, "Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk", Mol Neurodegener, 12, pp.43~ (2017)
- Profenno LA, "Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders", Biol Psychiatry, 67, pp.505~512 (2010)
- Karch CM, "Alzheimer’s disease risk genes and mechanisms of disease pathogenesis", Biol Psychiatry, 77, pp.43~51 (2015)
- Menke A, "Prevalence of and trends in diabetes among adults in the United States, 1988-2012", JAMA, 314, pp.1021~1029 (2015)
- Kapasi A, "Impact of multiple pathologies on the threshold for clinically overt dementia", Acta Neuropathol, 134, pp.171~186 (2017)
- Oh M, "Clinical evaluation of 18F-PI-2620 as a potent PET radiotracer imaging tau protein in Alzheimer disease and other neurodegenerative diseases compared with 18F-THK-5351", Clin Nucl Med, 45, pp.841~847 (2020)
- Bullich S, "Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment", Neuroimage Clin, 15, pp.325~332 (2017)
- Sabri O, "Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease : phase 3 study", Alzheimers Dement, 11, pp.964~974 (2015)
- THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia, "Eur J Nucl Med Mol Imaging", 2018, 432~442
- White L, "Recent clinical-pathologic research on the causes of dementia in late life : update from the Honolulu-Asia Aging Study", J Geriatr Psychiatry Neurol, 18, pp.224~227 (2005)
- Apostolova LG, "Critical review of the appropriate use criteria for amyloid imaging: effect on diagnosis and patient care", Alzheimers Dement(Amst), 5, pp.15~22 (2016)
- -florbetapir(INDIAFBP)study, "JAMA Neurol", 2016, 1417~1424
- Rabinovici GD, "Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia", JAMA, 321, pp.1286~1294 (2019)
- THK5351 PET Imaging in Patients with Mild Cognitive Impairment, "Journal of Clinical Neurology", 2020, 202~214, pp.대한신경과학회
- Lee HJ, "Identification of heterogeneous subtypes of mild cognitive impairment using cluster analyses based on PET imaging of tau and astrogliosis", Front Aging Neurosci, 12, pp.615467~ (2021)